Overall, immunotherapy in SFTs remains investigational, with limited efficacy observed to date due to their immunologically ‘cold’ nature, low mutational burden and scarce PD-L1 expression, these features are further supported by the limited or absent expression of cancer/testis antigens such as NY-ESO-1 and MAGE-A427 – antigens shown to be rarely expressed in SFTs compared to other high-grade sarcomas – suggesting that future benefit may depend on combinatorial strategies aimed at enhancing tumour immunogenicity. The gene discussed is CD274; the disease is neoplasm.